Neurologically Potent Molecules from *Crataegus oxyacantha*; Isolation, Anticholinesterase Inhibition, and Molecular Docking

Mumtaz Ali1*, Sultan Muhammad1, Muhammad R. Shah2, Ajmal Khan3,4*, Umer Rashid3, Umar Farooq3, Farhat Ullah5, Abdul Sadiq6, Muhammad Ayaz6, Majid Ali3, Manzoor Ahmad1 and Abdul Latif1*

OPEN ACCESS

Edited by:
Anna Rita Bilia,
University of Florence, Italy

Reviewed by:
Eleni Skaltsa,
National and Kapodistrian University of Athens, Greece

Benedict Green,
Agricultural Research Service (USDA), United States

*Correspondence:
Mumtaz Ali mumtazphd@gmail.com; mumtazali@uom.edu.pk
Abdul Latif
dralatif2016@gmail.com; ajmalchemist@yahoo.com
Ajmal Khan
ajmalkhan@ciit.net.pk

Specialty section:
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

Received: 27 December 2016
Accepted: 16 May 2017
Published: 07 June 2017

Citation:
Ali M, Muhammad S, Shah MR, Khan A, Rashid U, Farooq U, Ullah F, Sadiq A, Ayaz M, Ali M, Ahmad M and Latif A (2017) Neurologically Potent Molecules from *Crataegus oxyacantha*; Isolation, Anticholinesterase Inhibition, and Molecular Docking. Front. Pharmacol. 8:327, doi: 10.3389/fphar.2017.00327

*Crataegus oxyacantha* is an important herbal supplement and famous for its antioxidant potential. The antioxidant in combination with anticholinesterase activity can be considered as an important target in the management of Alzheimer’s disease. The compounds isolated from *C. oxyacantha* were evaluated for cholinesterases inhibitory activity using Ellman’s assay with Galantamine as standard drug. Total of nine (1–9) compounds were isolated. Compounds 1 and 2 were isolated for the first time from natural source. Important natural products like β-Sitosterol-3-O-β-D-Glucopyranoside (3), lupeol (4), β-sitosterol (5), betulin (6), betulinic acid (7), oleanolic acid (8), and chrysin (9) have also been isolated from *C. oxyacantha*. Overall, all the compounds exhibited an overwhelming acetylcholinesterase (AChE) inhibition potential in the range 5.22–44.47 µM. The compound 3 was prominent AChE inhibitor with IC50 value of 5.22 µM. Likewise, all the compounds were also potent in butyrylcholinesterase (BChE) inhibitions with IC50s of up to 0.55–15.36 µM. All the compounds, except 3, were selective toward BChE. Mechanism of the inhibition of both the enzymes were further studied by docking procedures using Genetic Optimization for Ligand Docking suit v5.4.1. Furthermore, computational blood brain barrier prediction of the isolated compounds suggest that these are BBB+

Keywords: *Crataegus oxyacantha*, Alzheimer’s disease, acetylcholinesterase (AChE) inhibition, butyrylcholinesterase (BChE) inhibition, molecular docking, pharmacokinetic properties

INTRODUCTION

Neurodegenerative disorders affecting a huge number of elder population worldwide (Novakovic et al., 2013). The etiology of neuronal death in these diseases remains inexplicable (Beal, 1995). The onset of these diseases is quite dangerous with gradual progression (Howes et al., 2003). The disorders include Alzheimer’s disease (AD), Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and cerebellar degenerations (Beal, 1995). Of these, AD is a chronic neurodegenerative disorder and is the most common type of dementia (Yoshita et al., 2001). AD is supposed to be account for 50–60% of dementia cases in elderly patients (Francis et al., 1999). Major
symptoms associated with AD are memory loss, behavioral turbulence and mood disturbance in routine life (Kumar et al., 1998). Several biochemical pathways are followed for the management of AD but one of the most established approach is the inhibition of acetylcholinesterase (AChE) (Zeb et al., 2014; Ahmad et al., 2015; Kamal et al., 2015; Sadiq et al., 2015). The AChE is found in excitable tissues in most erythrocytes and in the placental tissues while butyrylcholinesterase (BChE) is present in nervous system, liver and plasma (Massoulí et al., 1993). In cholinergeric synapse, a vital neurotransmitter acetylcholine (ACh) is break down into acetyl group and choline by AChE and BChE (Voet and Voet, 1995). The reduction of ACh concentrations in the hippocampus and cortex of brain can bring a vital biochemical change in AD patients (Jaén et al., 1996). Therefore, a key target in the management of AD is the inhibition of AChE and BChE (Schneider, 1995). Several cholinesterase inhibitors from natural and synthetic sources are available like galantamine, donepezil, rivastigmine, and tacrine (Schulz, 2003). Numerous researchers have also shown that oxidative stress is an early pathogenic event in AD (Sadiq et al., 2015). Therefore, they supplement their anticholinesterase with antioxidants as free radicals scavengers. A constant research is going in the field of AD, which brought several reports from natural product sources and synthetic source (Ayaz et al., 2014; Sadiq et al., 2015). However, most of these remedies are associated with severe side effects, low efficacy or availability. Therefore, the researchers working on AD are in constant search of novel, safe, effective, and economical origin of drugs.

Recently, galantamine isolated from several species of Amaryllidaceae family including Galanthus species, Leucojum species, and Narcissus species was effectively marketed for the symptomatic relief of AD (Parys, 1998). Galantamine mediate its therapeutic effect via reversible inhibition of acetyl cholinesterase (AChE) and allosterically mediate the action of nicotinic cholinergic receptors (nAChRs). Its selectivity against cholinesterase of different origin is variable. For instance the galantamine selectivity against human erythrocytes (RBCs) based AChE is fifty three times greater than plasma based BChE. Furthermore, galantamine exhibited 10 times lower potency against human brain based AChE as compared to RBCs variant (Harvey, 1995).

Crataegus oxyacantha, a flowering shrub of Rosaceae family is medicinally used as cardiovascular tonic, anti-hypertensive and agent to induce blood lipid profile (Weihmayer and Ernst, 1996). This plant, also known as hawthorn is an economical and rich source of triterpenic acids, ursolic acid, oleanolic acid, polyphenols like procyanidins, epicatechin, hyperoside, isoquercitrin, chlorogenic acid, and other important organic molecules (Cui et al., 2006). In this piece of research work, we have isolated bioactive compounds from the aerial parts of C. oxyacantha. Furthermore, the purified compounds after structure confirmations were subjected to anticholinesterase inhibition assay.

In the current study we have isolated two new (1 and 2) and seven (3–9) reported compounds from the C. oxyacantha. C. oxyacantha is herbal supplement and is mainly known for its antioxidant, antimicrobial, anti-inflammatory, gastroprotective, and anti-arrhythmic potentials (Tankanow et al., 2003; Tadici et al., 2008; Kashyap et al., 2012; Kostič et al., 2012). The compound 3 isolated from C. oxyacantha, also called β-sitosterol-3-O- β -D-glucopyranoside is majorly reported with antitumor (Guevara et al., 1999), antiprotozoal (Alanis et al., 2003), antimicrobial (Kuete et al., 2007), and as DNA polymerase inhibitor ( Mizushima et al., 2006). Lupeol a naturally occurring triterpenoid is recently identified and quantified by HPLC analysis in the hawthorn ethanolic extract (Rezaei-Golmisheh et al., 2015). Lupeol (4) has been studied for its possible use in hepatoprotective (Sunitha et al., 2001), anti-inflammatory ( Fernández et al., 2001), anticancer (Saleem et al., 2001, 2004), and in inhibition of protein tyrosine phosphatase (Na et al., 2009). An important phytoester, i.e., β-sitosterol (5) was also isolated from C. oxyacantha. β-Sitosterol mostly found in vegetable oil, nuts, and avocados has also been reported with clinical trial for it possible use in the management of benign prostatic hyperplasia ( Berges et al., 1995). Betulin (6) can be easily converted to its structure analog betulinic acid (7) and those compounds are reported with identical activities like antimalarial ( Alakurtti et al., 2006), anti-inflammatory ( Alakurtti et al., 2006), anticancer ( Alakurtti et al., 2006), antiviral ( Pavlova et al., 2003), and as anti-AIDS ( Sun et al., 1998). The oleanolic (8) and ursolic acids are famous for their reported activities like hepatoprotective, anti-inflammatory, antihyperlipidemic, antioxidant, and antitumor effects ( Liu, 1995). C. oxyacantha is a rich source of flavonoids ( Li et al., 2009). Chrysins (9), naturally occurring flavonoid is majorly reported for its possible use in the management of cancer ( Zheng et al., 2003), anxiety ( Brown et al., 2007), inflammation (Woo et al., 2005), and in behavioral effects ( Zanoli et al., 2000). Based on the literature survey it can be obviously scrutinized that there is no report available on the acetyl or BChE inhibitions of the compounds isolated from C. oxyacantha.

MATERIALS AND METHODS

General Information

Column Chromatography was used to purify the compounds using silica gel (E. Merck, 70–300 mesh) and flash silica gel (E. Merck, 230–400 mesh). Thin-layer chromatography (TLC) was carried out pre-coated aluminum sheets (60 F254, E. Merck). Purity of the compounds was also checked on the same pre-coated plates visualized under UV light (254 and 366 nm). UV spectra were obtained on Optima SP3000 plus (Japan) using chloroform and methanol as solvent. IR spectra were analyzed on an Elmer Fourier-Transform spectrometer, using KBr plates. 1H, 13C NMR, and 2D-NMR (HMOC, HMB, NOSEY, and COSYE) spectra were recorded on a JEOLI ECA 600 (United States) and Bruker AV 500 (Germany) spectrometers. Tetramethylsilane (TMS) was used as an internal standard and Chemical shifts (δ) were expressed in ppm relative to TMS.

Plant Material

Crataegus oxyacantha was collected from local area of Pashtonai (72° 18’ 36” E, 35° 03’18” N), KP, Pakistan in June 2013
during flowering season. Plant was identified by Prof. Mahboob Ur Rehman, Govt. Jehanzeb College Swat. Voucher specimen (C-124) was retained for verification purpose in herbarium of the College.

Extraction and Isolation
Plant twigs were shade dried at room temperature and chopped. Dry powdered plant (22 Kg) was extracted with methanol (3 L × 30 L) at room temperature. The methanolic extract was concentrated under reduced pressure at 50°C using rotary evaporator (R-301, Buchi) and obtained a gummy extract (1 Kg). The extract was suspended in water and successively partitioned to hexane, dichloromethane, ethyl acetate, and butanol fractions. DCM soluble fraction was subjected to column chromatography over silica gel using n-hexane: ethyl acetate and ethyl acetate: hexane: ethyl acetate: hexane gradient. From the column chromatography over silica gel, nine substances were isolated under high performance liquid chromatography, namely Lupeol (4), ß-Sitosterol (5), 3ß, 28-Dihydroxylup-20(29)-ene (Betulinic acid) (6), and the three glycosides 3ß-O-ß-D-Glucopyranoside (3) and 3ß-O-ß-D-Glucopyranoside (3) and 3ß-O-ß-D-Glucopyranoside (3).

3ß, 28-Dihydroxylup-20(29)-ene (Betulinic acid) (6)
White amorphous powder; IR (KBr): δ max: 3406, 1645, 1495, 1381, 1183, 1104, 1039, 985, 940 cm⁻¹. Molecular formula: C₃₀H₅₀O₇; EI-MS m/z: 426 [M⁺] (calcd. 426.0000 for C₃₀H₅₀O₇); ¹H-NMR (CDCl₃, 300 MHz): δ 1.69 (2H, dd, J = 6.12 Hz, H-1), 1.37 (2H, m, H-2), 3.16 (1H, dd, J = 11.46 Hz, 4.8 Hz, H-3), 0.66 (1H, m, H-5), 1.37 (2H, m, H-6), 1.37 (2H, m, H-7), 1.24, 1.27 (1H, m, H-9, 1.55 (2H, m, H-11), 1.66 (2H, m, H-12), 0.89, 1.69 (1H, m, H-13), 1.55 (2H, d, H-15), 1.37 (2H, m, H-16), 1.32 (1H, d, H-18), 2.37 (1H, m, H-19), 1.24 (2H, q, H-21), 1.18 (2H, m, H-22), 0.95 (3H, s, Me-23), 0.81 (2H, s, H-24), 1.01 (3H, s, Me-25), 0.74 (3H, s, Me-26), 0.93(3H, s, Me-27), 0.77 (3H, s, Me-28), 4.46 (2H, m, H-29), 1.66 (3H, s, Me-30).

3ß-O-ß-D-Glucopyranoside (3)
White amorphous powder; IR (KBr) δ max: 3406, 2905, and 1640 cm⁻¹. Molecular formula C₂₃H₄₅O₁₀; EI-MS: m/z 418 [M⁺] (calcd. 417.0375 for C₂₃H₄₅O₁₀); ¹H-NMR (DMSO, 300 MHz): δ 1.07 (2H, dd, J = 6.12 Hz, H-1), 1.23, 1.48 (2H, m, H-2), 3.52 (2H, m, H-3), 1.98 (2H, t, H-4), 5.33 (1H, d, H-6), 1.42 (2H, m, H-7), 1.42 (1H, m, H-8), 0.84 (1H, m, H-9), 1.49, 1.47 (1H, m, H-11), 2.19 (2H, d, J = 2.1, H-12), 0.96 (1H, m, H-14), 1.52 (2H, m, H-15), 1.23 (3H, m, Me-16), 1.07 (1H, d, J = 7.8, H-17), 0.66 (3H, s, Me-18), 0.99 (3H, s, Me-19), 1.35 (1H, m, H-20), 0.90 (3H, d, J = 5.26 Hz, Me-21), 1.27 (2H, m, H-22), 1.14 (2H, m, H-23), 0.92 (1H, m, H-24), 1.26 (1H, m, H-25), 0.79 (3H, d, J = 6.8 Hz, Me-26), 0.81 (3H, d, J = 5.58 Hz, Me-27), 1.22 (2H, m, H-28), 0.82 (3H, t, J = 7.5 Hz, Me-3).

Lupeol (4)
White powder; FT-IR (neat) max: 3406, 1645, 1495, 1381, 1183, 1104, 1039, 985, 940 cm⁻¹. Molecular formula: C₃₀H₄₀O₆; EI-MS m/z: 426 [M⁺] (calcd. 426.0000 for C₃₀H₄₀O₆); ¹H-NMR (CDCl₃, 300 MHz): δ 1.69 (2H, dd, J = 6.12 Hz, H-1), 1.37 (2H, m, H-2), 3.16 (1H, dd, J = 11.46 Hz, 4.8 Hz, H-3), 0.66 (1H, m, H-5), 1.37 (2H, m, H-6), 1.37 (2H, m, H-7), 1.24, 1.27 (1H, m, H-9, 1.55 (2H, m, H-11), 1.66 (2H, m, H-12), 0.89, 1.69 (1H, m, H-13), 1.55 (2H, d, H-15), 1.37 (2H, m, H-16), 1.32 (1H, d, H-18), 2.37 (1H, m, H-19), 1.24 (2H, q, H-21), 1.18 (2H, m, H-22), 0.95 (3H, s, Me-23), 0.81 (2H, s, H-24), 1.01 (3H, s, Me-25), 0.74 (3H, s, Me-26), 0.93(3H, s, Me-27), 0.77 (3H, s, Me-28), 4.46 (2H, m, H-29), 1.66 (3H, s, Me-30).
FIGURE 1 | Isolated organic molecules from dichloromethane fraction of aerial parts of *Crataegus oxyacantha*.

(3H, s, Me-24), 0.81 (3H, s, Me-25), 0.95 (3H, s, Me-26), 0.93 (3H, s, Me-27), 4.66 (3H, s, Me-29), 1.68 (3H, s, Me-30).

**3β-Hydroxyurs-12-en-28-oic Acid (Oleanolic Acid) (8)**

Colorless crystals (CHCl₃–MeOH); IR (KBr) $\tilde{\nu}_{\text{max}}$: 3450 cm$^{-1}$, 1700 cm$^{-1}$; EI-MS m/z 456 [M$^+$, C$_{30}$H$_{48}$O$_3$]; $^1$H-NMR (DMSO, 300 MHz) $\delta$: 1.43 (2H, m, H-1), 1.61 (2H, m, H-2), 3.44 (1H, dd, $J = 11.2, 5.5$ Hz, H-3), 1.37 (1H, m, H-5), 1.38 (2H, m, H-6), 1.43 (2H, m, H-7), 1.44 (1H, m, H-9), 1.90 (2H, m, H-11), 5.50 (2H, Brs, H-12), 1.24 (2H, m, H-15), 1.47 (2H, m, H-16), 2.53 (1H, d, $J = 12.0$ Hz, H-18), 1.34 (2H, m, H-19), 1.43 (2H, m, H-21), 1.87 (2H, m, H-22), 1.24 (3H, s, Me-23), 1.01 (3H, s, Me-24), 0.88 (3H, s, Me-25), 1.03 (3H, s, Me-26), 1.30 (3H, s, Me-27), 0.94 (3H, d, $J = 6.2$ Hz, Me-29), 1.02 (3H, s, Me-30).

**In Vitro Cholinesterase Inhibitory Assays**

*In vitro* cholinesterase inhibitory potentials of our test compounds were evaluated using Ellmans assay (Ellman et al., 1961; Ayaz et al., 2015). Basic principle of this procedure is reliant on catalytic degradation of substrates including acetylthiocholine iodide and butyrylthiocholine iodide by the respective enzymes AChE and BChE to form 5-thio-2-nitrobenzoate anion which is subsequently complexed with DTNB to form a yellow color compound. This yellow compound is UV detectable and is quantified with the passage of time with and without the impact of inhibitor agent. Briefly, from each enzyme solution, 5 $\mu$l were added to wells of micro plate and 5 $\mu$l DTNB was added to it. The resultant mixture was incubated for 15 min at 30°C in water bath followed by addition of 5 $\mu$l substrate solution.
Finally, absorbance was measured at 412 nm using micro plate reader. Control contains all solutions except inhibitor. Change in absorbance was recorded along with reaction time. At the end, Enzymes and enzymes inhibitory activities by control and our test samples were calculated from the rate of absorption with change in time as \( V = \Delta \text{Abs} / \Delta t \) and Enzyme inhibition as; Percent Enzyme activity = \( V/V_{\text{Max}} \times 100 \).

Where, \( V_{\text{Max}} \) is enzyme activity in the absence of inhibitor agent.

### Molecular Modeling

The molecular construction of isolated compounds were performed using ChemBioDraw Ultra 14 suite (PerkinElmer Inc.) and converted into 3D conformations by ChemBio3D (Mills, 2006). Molecular docking simulations of isolated compounds were carried out using GOLD (Genetic Optimization for Ligand Docking) (version 5.4.1) (Verdonk et al., 2003) software, with goldscore_p450_csd template. Goldscore was selected as a fitness function. Docking search area was sphere of radius 6 Å. Crystal structures of the enzymes, AChE (PDB: 1EVE) and BChE (PDB: PDB Code 1P0I) used for protein–ligand interactions, were retrieved from Protein Data Bank (PDB). The target proteins were prepared by the addition of hydrogen, removal of water and the removal of cocrystallized ligands. All other parameters were used with the default settings. The ligand-bound sites of the enzymes were used as possible binding sites.

| TABLE 1 | Results of in vitro cholinesterase inhibitory assays on the isolated compounds. |
| --- | --- |
| **Compound** | **Concentration (µg/ml)** | **% AChE inhibition IC\(_{50}\) (µM ± SEM)** | **% BChE inhibition IC\(_{50}\) (µM ± SEM)** | **AChE\(^a\) selectivity** | **BChE\(^b\) selectivity** |
| 1 | 250 | 97.32 ± 1.06 | 90.65 ± 1.34 | | |
| | 125 | 95.70 ± 1.25 | 87.44 ± 0.58 | 2.41 ± 0.09 | 0.10 | 9.62 |
| | 62.5 | 89.65 ± 1.47 | 84.28 ± 2.19 | | |
| 2 | 250 | 93.05 ± 0.75 | 95.76 ± 0.71 | | |
| | 125 | 92.74 ± 1.29 | 91.23 ± 1.83 | 15.36 ± 1.01 | 0.59 | 1.69 |
| | 62.5 | 83.74 ± 0.68 | 87.56 ± 1.06 | | |
| 3 | 250 | 95.70 ± 1.60 | 94.84 ± 0.30 | | |
| | 125 | 91.90 ± 0.43 | 88.94 ± 1.13 | 11.83 ± 0.93 | 2.26 | 0.47 |
| | 62.5 | 87.90 ± 0.52 | 83.03 ± 0.36 | | |
| 4 | 250 | 93.73 ± 0.78 | 91.42 ± 0.43 | | |
| | 125 | 90.37 ± 1.65 | 89.91 ± 0.88 | 1.31 ± 0.12 | 0.04 | 27.71 |
| | 62.5 | 77.87 ± 0.26 | 85.80 ± 1.50 | | |
| 5 | 250 | 91.33 ± 0.49 | 92.58 ± 1.12 | | |
| | 125 | 86.67 ± 0.89 | 90.00 ± 0.00 | 0.56 ± 0.03 | 0.04 | 26.62 |
| | 62.5 | 80.00 ± 0.00 | 87.08 ± 0.47 | | |
| 6 | 250 | 96.13 ± 0.20 | 95.85 ± 2.25 | | |
| | 125 | 94.03 ± 0.48 | 93.72 ± 1.01 | 25.63 ± 1.25 | 1.06 | 0.93 |
| | 62.5 | 84.00 ± 1.15 | 82.45 ± 0.90 | | |
| 7 | 250 | 95.70 ± 1.60 | 94.10 ± 0.60 | | |
| | 125 | 91.90 ± 0.43 | 90.25 ± 1.40 | 3.48 ± 0.15 | 0.07 | 12.78 |
| | 62.5 | 77.70 ± 1.25 | 87.22 ± 1.28 | | |
| 8 | 250 | 95.05 ± 0.75 | 93.08 ± 1.04 | | |
| | 125 | 92.00 ± 0.98 | 89.93 ± 0.67 | 5.16 ± 0.13 | 0.13 | 7.52 |
| | 62.5 | 79.62 ± 1.67 | 85.59 ± 3.28 | | |
| 9 | 250 | 93.67 ± 0.88 | 85.00 ± 0.00 | | |
| | 125 | 90.76 ± 0.61 | 82.00 ± 1.15 | 0.63 ± 0.06 | 0.02 | 51.27 |
| | 62.5 | 81.20 ± 0.23 | 80.90 ± 1.90 | | |
| Galantamine | 250 | 96.62 ± 1.67 | 95.33 ± 1.09 | | |
| | 125 | 92.91 ± 1.30 | 92.50 ± 1.04 | 10.0 ± 0.10 | 1.25 | 0.8 |
| | 62.5 | 89.87 ± 1.27 | 87.83 ± 1.01 | | |

\(^a\)Selectivity Index for AChE = IC\(_{50}\) ratio (BChE/AChE). \(^b\)Selectivity Index for BChE = IC\(_{50}\) ratio (AChE/BChE).

| TABLE 2 | Physico-chemical descriptors of the isolated compounds (1–9). |
| --- | --- |
| **Compound no.** | MW | LogP | HBD | HBA | nROT | tPSA | BBB |
| 1 | 212.25 | 0.61 | 1 | 4 | 5 | 47.9 | +ve |
| 2 | 196.2 | 0.14 | 2 | 4 | 4 | 66.76 | +ve |
| 3 | 576.86 | 5.48 | 6 | 9 | 99.38 | −ve |
| 4 | 426.73 | 7.73 | 1 | 1 | 1 | 20.23 | +ve |
| 5 | 412.75 | 9.29 | 2 | 0 | 6 | 0.00 | +ve |
| 6 | 442.73 | 6.43 | 2 | 2 | 2 | 40.46 | +ve |
| 7 | 456.71 | 6.96 | 3 | 2 | 57.53 | +ve |
| 8 | 456.71 | 7.02 | 3 | 1 | 57.53 | +ve |
| 9 | 254.24 | 2.4 | 2 | 4 | 1 | 70.67 | +ve |
Anticholinesterase Inhibitors from Crataegus oxyacantha

RESULTS

The C. oxyacantha was collected from the district Swat of Pakistan. The crude extract of the plant was obtained using its aerial parts. Based on the initial screening, TLC analysis and quantity of the dichloromethane fraction (80 g), this fraction was selected for isolation of bioactive among other solvent fractions. Initially, the TLC analyzed DCM fraction was subjected to a major chromatography which resulted in semi-purified organic molecules. Then by using a small scale column chromatography for all of individual samples resulted in isolation of nine organic molecules (compounds 1–9, Figure 1).

To the best of our literature survey we claim that compounds 1 [2-(3, 4-dimethoxyphenyl)-2-methoxyethanol] and 2 [3-hydroxy-1-(4-hydroxy-3-methoxyphenyl) propan-1-one] were obtained for the first time from the natural sources. The remaining seven compounds are pre-existing important natural products including β-Sitosterol-3-O-β-D-Glucopyranoside (3), lupeol (4), β-sitosterol (5), betulin (6), betulinic acid (7), oleanolic acid (8), and chrysin (9). All the isolated compounds are very important moieties in natural products.

In Vitro Pharmacology

Initially, we evaluated the dichloromethane fraction for its possible potential of inhibition the acetyl and BChEs. After getting encouraging results from the initial screening/extract, pure compounds (1–9) were subjected to the acetyl and BChE inhibitions as shown in Table 1.

In AChE inhibition assay, almost all of the compounds exhibited considerable results with IC_{50} values of greater
FIGURE 4 | Putative binding mode of 3 in the binding cavity of human AchE (PDB Code 4EY6). The structure reveals that compound 3 is embedded in the binding pocket of galantamine.

FIGURE 5 | (A) Stereoview of the docking pose of Betulinic acid (7, blue color stick model) in the binding pocket of AChE (1EVE). (B) 2D interactions of betulinic acid (7).

potency as shown in Table 1. In AChE inhibitory assays, Compounds 1, 6, 3, 7, 8 exhibited highest AChE inhibitory activities displaying 97.32 ± 1.06, 96.13 ± 0.20, 95.70 ± 1.60, 95.70 ± 1.60, and 95.05 ± 0.75% inhibitions at 250 µg/ml, respectively. The AChE inhibitory activities of these samples were very much comparable with the galantamine at the same concentrations Table 2. In BChE inhibition assay, 2, 3, 6, and 7 showed highest inhibitory activity with inhibitions of 95.76 ± 0.71, 94.84 ± 0.30, 95.85 ± 2.25, 94.10 ± 0.60, respectively. Percent inhibitions of our test compounds were more against AChE in comparison to BChE. Among the entire compound 3 showed the most prominent inhibition with IC$_{50}$ value of 5.22 µM. At the same three concentrations the standard drug Galantamine was observed with IC$_{50}$ = 8.0 µM. Newly isolated compounds 1, 2 displayed moderate activities with IC$_{50}$ values of 23.2 and 25.90 µM, respectively. The order of potency of the remaining compounds was 5 > 6 > 9 > 8 > 7 (Table 1).
A summary of the BChE inhibitions of compounds 1–9 is also shown in Table 1. In BChE assay all the compounds achieve lower IC_{50} values than that of the standard drug Galantamine. With exception of compounds 3 and 6, all the other isolated compounds exhibited excellent selectivity toward BChE (Table 1). Compounds 5 and 9 have shown the BChE inhibition in nano-molar range (IC_{50} = 0.55 and 0.63 µM, respectively). Compound 6 exhibited very little activity (IC_{50} = 25.63 µM). In the current study galantamine selectivity was definitely greater for AChE (56%) more than BChE as given in Table 1.

**Molecular Modeling Studies**

To gain insight into the mechanism of AChE and BChE inhibition, binding modes of the isolated compounds were explored by GOLD suit v5.4.1. There are a plenty of X-ray crystal structures of AChE in PDB like Drosophila melanogaster, Electrophorus electricus (eel), Torpedo californica (TcAChE), human (hAChE) and mouse in apo or with co-crystallized ligand. These crystal structures can be used for the designing of new AChE inhibitors. In the current study, we tried to present the possible mechanism of action of the isolated compounds. For this purpose, X-ray crystal structure of TcAChE and hAChE also studied. The X-ray crystallographic structure of TcAChE (PDB Code 1EVE) and hAChE (PDB Code 4EY6) in complex with donepezil and galantamine were used as enzyme structures. Superposition of the docked poses of the most active compound 3 into the binding pockets of TcAChE and hAChE is shown in Figure 2A. The binding mode analysis of isolated compound 3-TcAChE and 3-hAChE complex shows that the compound 3 have same binding orientation in binding pocket of TcAChE and hAChE.

Visual inspection of all the best docked pose of the most active compound 3 in the active site of 1EVE revealed that hydrocarbon chain is embedded into the hydrophobic slot formed by Trp279 and Leu282. Tetrahydropyran ring formed five conventional hydrogen bonding interactions with Gln69, Trp84, Tyr121, Ser122, and Gly123. Tetracyclic ring structure is sandwiched between bottleneck residue Phe330 and Tyr334 (Figure 3). Isolated compound 3 showed highest Gold fitness score (79.9353). To understand the mechanism, we also docked compound 3 into the binding hAChE co-crystallized with galantamine. Figure 4, reveals that it is embedded into the binding site of galantamine.

The binding mode of the compound 7 (Betulinic acid), the least active compound with IC_{50} value of 44.47 µM, was also analyzed. The carboxylic group of compound 7 formed conventional hydrogen bonding interactions with the catalytic triad residue (His440) and oxyanion hole residue (Gly118). It also established with the acidic residue Glu199 near the base of the gorge (Figure 5). The Gold fitness score for 7 is 47.8194.

For gaining insight into the mechanism of BChE inhibition, the X-ray crystallographic structure of human BChE...
In AChE activity, we have demonstrated that compound both hydrophobic alkyl chains as well as hydrophilic features. 

C. oxyacantha with highest activity was separated into nine compounds (Table 1). Amongst the compounds, β-sitosterol (5) was found highly active in BChE inhibition with IC50 value of 0.56 μM. This activity can be attributed to the docking positions of side chain and hydroxyl group of β-sitosterol at the distance of 1.6 Å.

Preliminary In Silico Pharmacokinetics

Poor pharmacokinetic properties are the main cause of failure of the drugs or lead compounds to enter the market. Prediction of in silico ADMET studies (prediction of the in vivo pharmacokinetics) as early as possible in the drug discovery process has now become imperative to develop drugs with improve oral bioavailability, reduced toxicity, and adverse side effects.

Lipinski criteria for oral absorption was computed by using Molinspiration online software. The analysis of the Lipinski’s descriptors tabulated in Table 2 indicated compound 3 have molecular weight >500. Isolated compounds 3–8 violated the Lipinski’s Ro5 due to their logP value > 5 (Table 2, highlighted in red). Compound 3 is predicted to be the most lipophilic compound due to its high value of logP. Polar surface area is another important criteria for the determination of BBB penetration. According to Waterbeemd the cutoff value is 90 Å2 or less [1]. Compound 3 violates the criteria for cutoff value of tPSA (99.38). Number of rotatable bonds (nROT) is an additional property that measures the flexibility of the molecule. It can also be used as a filter in the ADME predictions. The drugs that penetrate BBB usually reported to have fewer nROT counts.

CONCLUSION

Herein, we claim that C. oxyacantha is a rich source of neurologically potent organic molecules. The isolated compounds from C. oxyacantha are evaluated for the first time for its possible use in acetyl and BChE inhibitions. All the isolated compounds showed an overwhelming acetyl and BChE inhibitions. There is good agreement found between in vitro experimental results and the docking scores.

AUTHOR CONTRIBUTIONS

MA and AL wrote the manuscript and also did spectral analyses and literature studies. SM performed plant collection and isolation of compounds. AK, UF, and UR performed computational studies. MS facilitated isolation of compounds and their mass and NMR spectra. FU, AS, MAy, and MAI were involved in doing biological activities. MAh did the final confirmation of the elucidated molecular structures.

ACKNOWLEDGMENTS

HEJ Research Institute University of Karachi Is acknowledged for facilitation in research and instrumentation. Dr. UR is thankful to The Cambridge Crystallographic Data Centre (CCDC) for providing license of GOLD suit to COMSATS Institute of Information Technology.
REFERENCES

Ahmad, S., Ullah, F., Ayaz, M., Sadiq, A., and Imran, M. (2015). Antioxidant and anticholinesterase investigations of Rumex hastatus D. Don: potential effectiveness in oxidative stress and neurological disorders. Biol. Res. 48, 20. doi: 10.1186/s40659-015-0010-z

Alcalde, S., Mäkelä, T., Koskimies, S., and Yli-Kauhaluoma, J. (2006). Pharmacological properties of the ubiquitous natural product betulina. Eur. J. Pharm. Sci. 29, 1–13. doi: 10.1016/j.ejps.2006.04.006

Alanis, A. D., Calzada, F., Cédillo-Rivera, R., and Meckes, M. (2003). Antiprotozoal activity of the constituents of Rubus coreanus. Phytother. Res. 17, 681–682. doi: 10.1002/ptr.1150

Ayaz, M., Junaid, M., Ahmed, J., Ullah, F., Sadiq, A., Ahmad, S., et al. (2014). Antioxidant and anticholinesterase investigations of crude extracts, subsequent fractions, saponins and flavonoids of Atropa belladonna L.: potential effectiveness in Alzheimer’s and other neurological disorders. Biol. Res. 48, 21. doi: 10.1186/s40659-015-0011-1

Kutev, V., Eyong, K., Folefoc, G., Beng, V., Hussain, H., Krohn, K., et al. (2007). Antimicrobial activity of the methanolic extract and of the chemical constituents isolated from Newboldia laevis. Pharmazie 62, 552–556.

Kumar, V., Durai, N., and Jobe, T. (1998). Pharmacologic management of Alzheimer’s disease. Clin. Geriatr. Med. 14, 129–146.

Li, H., Song, F., Xing, J., Tsao, R., Liu, Z., and Liu, S. (2009). Screening and structural characterization of α-glucosidase inhibitors from Hawthorn leaf flavonoids extract by ultrafiltration LC-DAD-MS and SORI-CID FTICR MS. J. Am. Soc. Mass Spectrom. 20, 1496–1503. doi: 10.1016/j.jasms.2009.04.003

Liu, J. (1995). Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 49, 57–68. doi: 10.1016/0378-8749(95)90032-2

Massoulié, J., Pizzimenti, L., Bon, S., Krejci, E., and Vallette, F.-M. (1993). Molecular and cellular biology of cholinesterases. Prog. Neurobiol. 41, 31–91. doi: 10.1016/0301-0082(93)90040-Y

Mills, N. (2006). ChemDraw Ultra 10.0 CambridgeSoft. 100 CambridgePark Drive, Cambridge, MA 02140. Commercial Price: 1910fordownload, 2150 for CD-ROM; Academic Price: 710fordownload, 800 for CD-ROM. J. Am. Soc. Mass Spectrom. 12, 1346–1365. doi: 10.1016/j.jms.2009.04.003

Na, M., Kim, B. Y., Osaka, S., and Ahn, J. S. (2009). Inhibition of protein tyrosine phosphatase 1B by lupenol and lupenone isolated from Sorbus commixta. J. Enzyme. Inhib. Med. Chem. 24, 1056–1059. doi: 10.1080/14756360802693312

Novaková, D., Fálická, M., Baca, O., Caruso, A., Piccinin, S., Schepisi, C., et al. (2013). Profile of gantumuramin and its potential in the treatment of Alzheimer’s disease. Drug Design. Ther. 7, 1359–1364. doi: 10.2147/DDDT.S33401

Pajuohesi, H., and Lenz, G. R. (2005). Medicinal chemical properties of successful central nervous system drugs. Neurol Res. 2, 541–553. doi: 10.1602/neurorex.2.541

Parys, W. (1998). Development of Reminyl® (galanthamine), a novel acetylcholinesterase inhibitor, for the treatment of Alzheimer’s disease. Alzheimers Rep. 53, 519–520.

Pavlov, N., Savinova, O., Nikolaeva, S., Boreko, E., and Flekhter, O. (2003). Antiviral activity of betulin, betulinic and betulonic acids against some enveloped and non-enveloped viruses. Fitoterapia 74, 489–492. doi: 10.1016/S0376-7375(03)00123-0

Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., et al. (2004). UCSF chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1622. doi: 10.1002/jcc.20084

Rezaei-Golmishesh, A., Malekeinjad, H., Asri-Rezaei, S., Farshid, A. A., and Akbari, P. (2015). Hawthorn ethanolic extracts with triterpenoids and flavonoids exert hepatoprotective effects and suppress the hypercholesterolemia-induced oxidative stress in rats. Iran. J. Basic Med. Sci. 18, 691–699.

Sadiq, A., Mahmood, F., Ullah, F., Ayaz, M., Ahmad, S., Haq, F. U., et al. (2015). Synthesis, anticholinesterase and antioxidant potentials of ketoesters derivatives of succinimides: a possible role in the management of Alzheimers’s disease. Chem. Cent. J. 9, 1–9. doi: 10.1186/s13065-015-0107-2

Saleem, M., Afzal, F., Adhami, V. M., and Mukhtar, H. (2004). Lupeol modulates Akt and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice. Oncogene 23, 5203–5214. doi: 10.1038/sj.onc.1207641

Saleem, M., Alam, A., Arifin, S., Shah, M. S., Ahmad, B., and Sultana, S. (2001). Lupeol, a triterpenic inhibitor, delays early responses of tumor promotion induced by benzoyl peroxide in murine skin. Pharm. Pharmacol. Res. 43, 127–134. doi: 10.1006/phrs.2000.7070

Schneider, L. S. (1995). New therapeutic approaches to Alzheimers’s disease. J. Clin. Psychiatry 57, 30–36.

Schulz, V. (2003). Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider. Phytomedicine 10, 74–79. doi: 10.1016/S1438-187X(03)00302

Sun, I.-C., Wang, H.-K., Kashwada, Y., Shen, J.-K., Cosentino, L. M., Chen, C.-H., et al. (1998). Anti-AIDS agents. 34. Synthesis and structure-activity relationships of betulin derivatives as anti-HIV agents. J. Med. Chem. 41, 4648–4657. doi: 10.1021/jm980391g
Sunita, S., Nagaraj, M., and Varalakshmi, P. (2001). Hepatoprotective effect of lupeol and lupeol linoleate on tissue antioxidant defence system in cadmium-induced hepatotoxicity in rats. *Fitoterapia* 72, 516–523. doi: 10.1016/S0367-326X(01)00259-3

Tadić, V. M., Dobrić, S., Marković, G. M., Đorđević, S. M., Arsić, I. A., Menković, N. A. R., et al. (2008). Anti-inflammatory, gastroprotective, free-radical-scavenging, and antimicrobial activities of hawthorn berries ethanol extract. *J. Agric. Food Chem.* 56, 7700–7709. doi: 10.1021/jf801668c

Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., and Taylor, R. D. (2003). Improved protein–ligand docking using GOLD. *Proteins* 52, 609–623. doi: 10.1002/prot.10465

Zanoli, P., Avallone, R., and Baraldi, M. (2000). Behavioral characterisation of the flavonoids apigenin and chrysin. *Fitoterapia* 71, S117–S123. doi: 10.1016/S0367-326X(00)00186-6

Zeb, A., Sadiq, A., Ullah, F., Ahmad, S., and Ayaz, M. (2014). Investigations of anticholinesterase and antioxidant potentials of methanolic extract, subsequent fractions, crude saponins and flavonoids isolated from *I. rugosus*. *Biol. Res.* 47:76. doi: 10.1186/0717-6287-47-76

Zheng, X., Meng, W.-D., Xu, Y.-Y., Cao, J.-G., and Qing, F.-L. (2003). Synthesis and anticancer effect of chrysin derivatives. *Bioorg. Med. Chem. Lett.* 13, 881–884. doi: 10.1016/S0960-894X(02)01081-8

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.